肌肉减少症与早期激素受体阳性乳腺癌女性辅助内分泌治疗毒性相关中断的关联
这项多中心回顾性队列研究纳入2011至2017年接受保乳手术、放疗及辅助内分泌治疗的305例0-II期激素受体阳性乳腺癌女性,中位随访89个月。肌肉减少症与毒性相关早期中断辅助内分泌治疗(OR 2.18,P=.036)及更短至毒性时间(HR 1.62,P=.031)相关。毒性相关中断与更差同侧乳腺肿瘤复发(HR 9.47,P=.002)和无病生存(HR 4.53,P=.001)相关。
要点
- 肌肉减少症与辅助内分泌治疗毒性相关早期中断相关(OR 2.18,P=.036)。
- 毒性相关中断与更差同侧乳腺肿瘤复发(HR 9.47)和无病生存(HR 4.53)相关。
- 肌肉减少症或骨骼肌指数未独立关联同侧乳腺肿瘤复发或无病生存。
核心结论
- 在接受辅助放疗和激素治疗的早期激素受体阳性乳腺癌女性中,肌肉减少症与毒性相关早期中断辅助内分泌治疗相关。
- 作者认为这些高风险患者可能是积极症状管理和/或替代治疗策略的候选者以改善结局。
- 作者指出需进一步研究在未接受辅助放疗的女性中验证这些发现。
研究设计与样本
- 多中心、回顾性队列研究,纳入2011至2017年连续接受保乳治疗(肿块切除和放疗)及辅助内分泌治疗的0-II期激素受体阳性乳腺癌女性,随访5年。
- 共纳入305例女性,中位随访89个月,中位年龄67岁,早期乳腺癌(0期12%,I期65%)。
- 通过深度学习模型在常规横断面放疗模拟影像上分析骨骼肌指数(SMI,cm2/m2),肌肉减少症根据既往验证报告二分。
- 主要终点为毒性相关辅助内分泌治疗中断,采用逻辑回归分析SMI/肌肉减少症与中断的关联。
- 采用Cox回归分析至辅助内分泌治疗毒性时间、同侧乳腺肿瘤复发和无病生存的关联。
主要发现
- 60例(20%)女性经历毒性相关辅助内分泌治疗中断。
- 肌肉减少症与毒性相关早期中断辅助内分泌治疗相关(OR 2.18,P=.036)。
- 肌肉减少症与更短至辅助内分泌治疗毒性时间相关(HR 1.62,P=.031)。
- SMI或肌肉减少症未独立关联同侧乳腺肿瘤复发或无病生存。
- 毒性相关辅助内分泌治疗中断与更差同侧乳腺肿瘤复发(HR 9.47,P=.002)和更差无病生存(HR 4.53,P=.001)相关。
关键数值与推荐
- 肌肉减少症与毒性相关早期中断辅助内分泌治疗的OR为2.18(P=.036)。
- 肌肉减少症与至辅助内分泌治疗毒性时间的HR为1.62(P=.031)。
- 毒性相关辅助内分泌治疗中断与同侧乳腺肿瘤复发的HR为9.47(P=.002)。
- 毒性相关辅助内分泌治疗中断与无病生存的HR为4.53(P=.001)。
临床怎么用
- 作者认为这些高风险患者可能是积极症状管理和/或替代治疗策略的候选者以改善结局。
- 作者指出需进一步研究在未接受辅助放疗的女性中验证这些发现。
局限性
- 作者指出需进一步研究在未接受辅助放疗的女性中验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized. METHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm2/m2) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS). RESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001). CONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.
引用
- Saraf A, Tahir I, Hu B, et al. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37506979. doi:10.1016/j.ijrobp.2023.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。